Rentschler Biopharma, a leading global CDMO for biopharmaceuticals, and Coriolis Pharma, a globally recognized CRDO specializing in formulation and drug product development, today announced a strategic collaboration.
Through this partnership, clients will gain access to integrated, end-to-end services that span early formulation work through commercial manufacturing. By combining the companies’ complementary strengths, the collaboration is designed to streamline development, lower tech-transfer risk, and accelerate the transition from research to clinical and commercial stages. The unified approach responds to increasing complexity in biologics and the demand for science-driven, interconnected development pathways.
Coriolis Pharma contributes advanced in silico and wet-lab formulation expertise, deep scientific knowledge, and sophisticated analytical capabilities. With a strong heritage in innovation and a commitment to scientific excellence, Coriolis supports all phases of drug development—from early R&D to GMP operations—making the company a reliable partner throughout the molecule’s lifecycle.
Rentschler Biopharma brings longstanding experience in bioprocess development and manufacturing for diverse biotherapeutics, supported by a proven record of quality and reliability. Known for its client-centric mindset, Rentschler provides robust support from process design to commercial supply, ensuring tailored, technically sound solutions at every project stage.
“This collaboration represents a meaningful milestone for both organizations and the clients and patients we serve. Coriolis Pharma shares our dedication to technical excellence, reliability, and a client-first approach. By integrating our strengths—bioprocess development and manufacturing with Coriolis’s formulation and analytical expertise—we can address complex biopharmaceutical challenges with greater speed and precision. This partnership perfectly reflects our mission of advancing medicine to save lives,” said Benedikt von Braunmühl, Chief Executive Officer, Rentschler Biopharma.
Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma, added: “At Coriolis, we believe scientific rigor, innovation, and meaningful partnerships are essential for advancing complex biopharmaceutical programs. Rentschler Biopharma’s development and manufacturing capabilities align seamlessly with our formulation and analytical strengths. This collaboration embodies our partnership philosophy—creating synergistic relationships across the biopharma landscape. Together, we will offer clients connected, science-driven solutions that help move their programs toward success.”
The integrated service offering will be available from December 2025. Both companies maintain operations in Germany and the United States, ensuring global accessibility and local support for clients in key biopharmaceutical markets.
